On October 22nd, an online discussion will take place, focusing on the operations of Russian businesses in the Middle East and North Africa (MENA) countries under sanctions pressure. The event is organized by the Legal Insight magazine and the Russian Export Center.

Dmitry Kirillov, Partner, Head of Tax and Customs practice at Lidings, will moderate the discussion session "Disputes with Tax Authorities or Defense in Tax Disputes".

Currently, the efforts of state authorities in the fields of pharmaceuticals and healthcare are also aimed at implementing the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030 (hereinafter referred to as the “Pharma 2030 Strategy”). One of the goals of the Pharma 2030 Strategy is to increase the share of domestically produced medicinal products in the total consumption volume from 61.8% to 66.6% by 2030. In this regard, measures to support Russian medicinal products manufacturers continue to be implemented.

On August 7, 2025, a draft law “On Amending the Federal Law ‘On Protection of Competition’” (hereinafter, the “Draft Law”) was published. Prepared by the Federal Antimonopoly Service (hereinafter, the “FAS”), it aims to significantly narrow the scope of antitrust immunities concerning the results of intellectual activity.

On 1 September 2025, a draft resolution of the Government of the Russian Federation “On approving the procedure and criteria for compiling a list of strategically significant medicines” (“Draft Resolution”) was submitted for public discussion.

Alina Smakova, Lidings associate specializing in personal data protection issues, will speak on the topic "Cross-Border Transfer of Personal Data: Building Bridges, Not Walls. Organizing Legal Cross-Border Data Flows".

The forum "Localization in Manufacturing" will take place on September 18-19. The event is dedicated to the localization challenges faced by all Russian goods manufacturers since January 1, 2025, following the enactment of Government Decree No. 1875.

Lidings is pleased to invite you and your colleagues to a seminar on launching new drugs in the Russian market.

Regulatory incentives and objective economic realities are driving pharmaceutical companies to seek opportunities for launching new drugs. Such projects are now being conceived and implemented not only by innovative companies but also by players who have traditionally specialized in generics and biosimilars.

During our seminar, we will share our experience and propose effective, cost-efficient legal solutions to help businesses safely and promptly execute new launches at any stage.